Pink Sheet is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Perrigo Gains Pole Position In Private-Label Allegra Race

This article was originally published in The Tan Sheet

Executive Summary

Perrigo cuts to the front of the queue for launching private-label versions of OTC Allegra, acquiring from Teva the exclusive U.S. sales and distribution rights to generic equivalents of the allergy drug

Related Content

In Brief
Perrigo Takes Two Steps Forward: Generic Allegra Launch, Manufacturing Compliance
Teva Stakes OTC Claim With P&G Joint Venture
Sanofi Allegra Switch Approval Triggers Race To Market For Perrigo
Perrigo Banks On Product Launches, OTC Switches For "Significant Growth"
Perrigo Absorbs Plant Remediation Sales Hit, But PBM Progresses In Q1
Claritin, Linens Make Strange Bedfellows But Licensing Revenue For Merck
Teva UK turns to OTCs
Perrigo's Generic Mucinex Becomes A Long Shot To Launch In Fiscal 2011
Perrigo Benefits From McNeil Recall, Prepares Infant Formula Launches





Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts